The combination of the ITK inhibitor BMS-509744 and conventional chemotherapies, such as vincristine or doxorubicin, acted synergistically to inhibit the proliferation of malignant T cells, indicating that combining ITK inhibition with CHOP may be a promising therapeutic regimen for the treatment of AITL. This evidence concerns the gene DDIT3 and angioimmunoblastic T-cell lymphoma.